Figure 5.

In vivo testing of the combination MK-1775 with Doxorubicin in two PDOX-MPNST mouse models for 18 days of treatment. A. Tumor reduction in the sporadic MPNST-SP-01 PDOX mouse model presented in two plots: the increased tumor volume since day 0 in each group during treatment, and tumor weight at the end of the experiment. The toxicity effect was assessed by changes in mouse body weight (Mann-Whitney test). B. Tumor reduction in the NF1-derived MPNST-NF1–09 PDOX mouse model presented in the same plots as A (Mann-Whitney test). The final tumor weight plot from MPNST-NF1–09 PDOX model presented less than 5 points in control and single treatments groups since several mice were left alive to study the regrowth of the tumor. However, all the mice were included in the plot representing tumor volume. C. Analyses of the molecular target of MK-1775 (P-Cdk1) and Doxorubicin (Cleaved Caspase-3) by Western Blot. CTL: mice treated with vehicle, Doxo: mice treated with Doxorubicin, MK: mice treated with MK-1775, M+D: mice treated with the combination MK-1775 and Doxorubicin, P-Cdk1: phosphorylation of Cdk1. ** p-value≤0.01, * p-value≤0.05.